Inhibition of 2C Coxsackie B Virus Protein to Decrease Pathogenicity of Diabetes Mellitus Type 1

Area of Science:

• Bioinformatics and computational drug discovery
• Virology and immunology
• Endocrinology and metabolic diseases

Background:

• Type 1 Diabetes (T1D) is an autoimmune condition causing insulin deficiency and hyperglycemia due to pancreatic beta cell loss.
• Genetic, immune, and environmental factors contribute to T1D, with Coxsackie B4 virus implicated as a potential environmental trigger.
• The presence of Coxsackie B4 virus in diabetic patients necessitates the investigation of viral inhibitors.

Purpose of the Study:

• To identify potential drug candidates targeting Coxsackie B4 virus in silico.
• To predict inhibitors for viral proteins associated with T1D.
• To lay the groundwork for developing novel therapeutic strategies against virus-induced T1D.

Main Methods:

• Utilized various bioinformatics databases, web servers, and software for protein structure generation, validation, and ligand analysis.
• Employed docking tools to determine protein target sites and analyze inhibitor interactions.
• Assessed drug-likeness properties including Lipinski, Veber, Ghose rules, QED, and BBB parameters.

Main Results:

• Identified two lead compounds, ZINC00034488 and ZINC00034585, as promising drug candidates.
• Confirmed that these compounds are non-toxic and exhibit favorable interaction energies with the target protein.
• Verified that the selected compounds adhere to established drug-likeness criteria (Lipinski, Veber, Ghose rules, QED, BBB).

Conclusions:

• The identified compounds offer a basis for understanding chemical interactions against Coxsackie B4 virus.
• This research aids in designing and testing novel drugs to combat T1D caused by Coxsackie B4 virus.
• Provides valuable insights for future therapeutic development against virus-associated autoimmune diabetes.